招银国际发表研究报告指,复宏汉霖(02696.HK) 上半年收入按年升3%至28.2亿元人民币,符合预期,其中药物销售25.7亿元人民币,达该行全年预测的49%,纯利按年升1%至3.9亿元人民币,达该行全年预测的31%。该行指,随着复宏汉霖的生物仿制药在中国和全球持续产生现金流入,集团正发展成为以HLX43为主导的创新生物制剂公司。该行表示,将其目标价由61.98元上调至97.75元,其评级为“...
Source Link招银国际发表研究报告指,复宏汉霖(02696.HK) 上半年收入按年升3%至28.2亿元人民币,符合预期,其中药物销售25.7亿元人民币,达该行全年预测的49%,纯利按年升1%至3.9亿元人民币,达该行全年预测的31%。该行指,随着复宏汉霖的生物仿制药在中国和全球持续产生现金流入,集团正发展成为以HLX43为主导的创新生物制剂公司。该行表示,将其目标价由61.98元上调至97.75元,其评级为“...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.